SXISTANDEX INTERNATIONAL CORP/DE/(SXI)Stock Analysis

AI analysis on 2,800+ stocks →
IndustrialsNYSE
Institutional-grade research for retail investors
SEC EDGAR: CIK 310354SXI stock profile & AI dashboard →

13F Pro Quality Score

68.2/100

Rank #424 of 2,860 stocksTOP 25%

View Industrials peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

71.4/100

Profitability

79.7/100

Balance Sheet

77.8/100

Earnings Quality

74.0/100

Free Cash Flow

46.7/100

Institutional Flow

76.9/100

Revenue Scale

46.9/100

Dilution Risk

94.9/100

SXI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for STANDEX INTERNATIONAL CORP/DE/ (SXI), a Industrials sector company. 13F Pro's AI-powered ranking engine scores SXI at 68.2/100 on a 32-signal composite quality model, placing it at rank #424 of 2,860 stocks — the top 25% of the AI-ranked universe. SXI scores in the top quartile across profitability (79.7), balance sheet strength (77.8), institutional flow (76.9). Based on the latest XBRL financial filings (Q3 2026), STANDEX INTERNATIONAL CORP/DE/ reports quarterly revenue of $224.6M, net income of $67.0M, free cash flow of $6.2M. Top institutional holders of SXI by reported 13-F value include BlackRock,, WASATCH ADVISORS, Neuberger Berman Group, based on the most recent SEC filings. SXI trades on the NYSE exchange and files with the SEC under CIK 310354. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SXI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STANDEX INTERNATIONAL CORP/DE/ directly from SEC EDGAR.

Fun facts about STANDEX INTERNATIONAL CORP/DE/

Quirks, history, and lore behind SXI — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A U.S. industrial conglomerate · mid-cap · listed on NYSE · headquartered in New Hampshire.
  • 2
    The Numbers
    Annual revenue in the range of $600–$700 million, spread across multiple niche industrial segments — none of them famous, all of them quietly essential.
  • 3
    The History
    Traces its roots back to the 1950s, built over decades through acquisitions of specialty manufacturers — the kind of company that grows by buying other companies nobody else is fighting over.
  • 4
    The Secret
    Its portfolio spans engineered components for markets like food service equipment, hydraulics, electronics, and engraving — a grab-bag that somehow coheres into steady operating margins.
  • 5
    The Lore
    Its Engraving Group is a global leader in mold texturing and surface finishing — meaning it quietly shapes the look of plastic parts on products you touch every day.
  • 6
    The Giveaway
    The ticker is SXI, the name sounds like a financial holding firm, and its full legal name ends in "International Corp/DE" — meet Standex, the most obscure conglomerate you've never heard of.
▶ Think you know your stocks? Play the Daily Ticker

What's Driving SXI's Business? Latest 10-Q Breakdown

AI-extracted from STANDEX INTERNATIONAL CORP/DE/'s 10-Q filed 2026-05-06 — Q3 FY2026 (nine months ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Nine-month revenue of $663.3M (+16.8% YoY) driven by $66.9M from acquisitions and $56.8M gain on Federal Industries divestiture, with operating income surging 165% to $156.0M.

Biggest Revenue Drivers

Total revenue: $663.3M+16.8% YoY

Electronics$345.9M+21.4% YoY

Acquisitions contributed $44.5M; organic growth +5.4% from fast-growth markets and new products

Engraving & Hydraulics$139.9M+5.7% YoY

Organic sales +3.2% from improved demand in Europe, North America and Asia

Aerospace & Defense$97.1M+37.7% YoY

McStarlite acquisition added $17.5M; organic growth +12.2% from space and aviation markets

Scientific$56.9M+4.5% YoY

Custom Biogenic Systems acquisition added $4.8M, offset by organic decline from NIH funding cuts

Largest Expense Items

Cost of sales$388.7M+12.9% YoY

Gross margin improved to 41.4% from 39.4% due to pricing disciplines and productivity actions

Selling, general, and administrative$162.4M+15.3% YoY

Increased by acquisition expenses, R&D, and higher U.S. medical costs

Restructuring costs$9.4M+136.7% YoY

Facility rationalizations and announced closure of four sites in Engraving & Hydraulics

Margins: Gross margin expanded 200 basis points to 41.4% from 39.4% year-over-year, driven by pricing disciplines and productivity initiatives across segments. Operating margin benefited significantly from the $56.8M gain on Federal Industries divestiture and acquisition contributions, though underlying operational performance showed disciplined margin management amid integration activities.

Watch Items from the Filing

  • Redeemable noncontrolling interest in Narayan (9.9%) remeasured at $44.2M as of March 31, 2026, with $18.8M adjustment in nine-month period based on contractual redemption value; potential future redemption obligations.
  • Scientific segment organic decline of $2.3M driven by NIH funding cuts affecting academic and research institutions; margin compressed from 24.5% to 22.6% nine-month YoY.
  • Debt of $472.8M at March 31, 2026 (down from $552.5M June 30, 2025); leverage ratio 2.18:1 and interest coverage 4.54:1, both within covenants but elevated debt from acquisitions.
  • Tariff exposure acknowledged as impacting multiple segments; company evaluating impact of Supreme Court decision on certain IEEPA tariffs with uncertain refund timing and amounts.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Revenue

Q3 2026

$224.6M

Net Income

Q3 2026

$67.0M

Free Cash Flow

Q3 2026

$6.2M

ROIC

Q3 2026

7.4%

D/E Ratio

Q3 2026

0.63

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+9.6% YoY
$790.1MFY 2025
FY21 $656.2MFY23 $741.0MFY24 $720.6MFY25 $790.1M

Net Income

-23.7% YoY
$55.8MFY 2025
FY21 $36.5MFY23 $139.0MFY24 $73.1MFY25 $55.8M

Operating Income

-8.0% YoY
$93.5MFY 2025
FY21 $59.2MFY23 $171.1MFY24 $101.7MFY25 $93.5M

EPS (Diluted)

-24.4% YoY
$4.64FY 2025
FY21 $2.97FY23 $11.58FY24 $6.14FY25 $4.64

Total Assets

+55.9% YoY
$1.57BFY 2025
FY21 $962.2MFY23 $1.02BFY24 $1.01BFY25 $1.57B

Total Debt

+271.1% YoY
$552.5MFY 2025
FY21 $199.5MFY23 $173.4MFY24 $148.9MFY25 $552.5M

Op. Cash Flow

-24.9% YoY
$69.6MFY 2025
FY21 $83.6MFY23 $90.8MFY24 $92.7MFY25 $69.6M

AI Insight: SXI Ratio Trends

Q1 2026 margins and returns spike dramatically—operating margin to 40.4%, ROIC to 29.6%—but quarter-to-quarter volatility and depressed Q4 2025 profitability raise sustainability concerns.

Operating margin surged to 40.4% in Q1 2026 from 16.1% in Q4 2025; net profit margin jumped to 29.8% from 1.0%.

ROIC expanded to 29.6% in Q1 2026 from 11.5% in Q4 2025; ROE and ROA also spiked to 35.5% and 17.5% respectively.

Leverage declined to 0.63 D/E in Q1 2026, down from 0.76–0.84 range in prior three quarters.

Q4 2025 showed severe profitability collapse—net margin fell to 1.0%, ROE to 1.2%—raising questions about Q1 2026 normalization.

Significant quarter-to-quarter volatility in profitability metrics (Q4 collapse, Q1 spike) suggests potential one-offs or seasonality masking underlying trends.

Track SXI with AI-powered research

10 AI analysts debate this stock daily. Free to start.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for STANDEX INTERNATIONAL CORP/DE/ including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Unlock Full Research for SXI

Get detailed financial analysis, insider activity, institutional flows, AI-powered debates, and quality rankings for STANDEX INTERNATIONAL CORP/DE/ and 2,800+ other companies.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is SXI a good stock to buy?

13F Pro's AI-powered analysis of STANDEX INTERNATIONAL CORP/DE/ (SXI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Industrials sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SXI are available on the SXI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SXI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SXI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of STANDEX INTERNATIONAL CORP/DE/'s investment landscape.